
Growth hormone axis research peptides
GHRH analogues and ghrelin-receptor secretagogues for pituitary-signalling research. The two classes act at different receptors on the same axis, which is why so many study designs pair one of each.
Growth Hormone Axis products






What is the difference between a GHRH analogue and a secretagogue?
GHRH analogues — sermorelin, tesamorelin, the CJC-1295 forms — act at the growth-hormone-releasing-hormone receptor. Secretagogues such as ipamorelin act at the ghrelin receptor. Because the receptors are distinct, a combination separates additive effects from independent ones.
What does the DAC in CJC-1295 do?
The drug affinity complex binds albumin and stretches the half-life from minutes to days. The no-DAC form, also called modified GRF (1-29), is used where a pulse rather than a plateau is wanted.
Why is ipamorelin described as selective?
It acts at the ghrelin receptor without the cortisol and prolactin release seen with earlier secretagogues, which keeps a comparison clean.
Where can I read more about these compounds?
Common questions about growth hormone axis
Which compound is the reference GHRH analogue?
Sermorelin — the first 29 residues of GHRH, the shortest fragment that keeps full receptor activity. The CJC-1295 forms are built on that same backbone.
Do the blends in this category use the DAC form?
No. The CJC-1295 blends here use the no-DAC form. Each product page states which.
Are these for human use?
No. Sold for in-vitro laboratory research only.
Every product in this category is sold for in-vitro laboratory research only and is not for human or animal consumption, diagnostic or therapeutic use.

